Marketresearchnews

Wednesday, 6 February 2019

Bioinformatics Market 2018 Market Challenge, Driver, Trends & Forecast to 2023

Market scenario:

Bioinformatics is the use of information technology in the field of biotechnology for the purpose of data storage, data warehousing and analyzing the DNA sequences. In bioinformatics technology knowledge about various branches is required which includes biology, mathematics, computer science, laws of physics & chemistry along with it most importantly sound knowledge about information technology is required to analyze biotechnological data.

Globally the market for bioinformatics is growing steadily and has a bright future, this market expected to grow at the rate of about 19.8% till 2022 and this has started since 2016.

Key Players for Bioinformatics Market:

Agilent Technologies,
Illumina, Inc.,
QIAGEN N. V, and Thermo Fisher Scientific Inc.,
Dassault Systèmes,
QIAGEN and others.

Segments:

Bioinformatics market has been segmented on the basis of application which comprises of genomics, chemoinformatics, drug design, transcriptomics, molecular phylogenetics, proteomics, metabolomics, DNA sequences and others. On the basis of services and technology the market is segmented into data warehousing, sequence analysis, sequence manipulation and others. On the basis of sector the market is divided into medical bioinformatics, animal bioinformatics, agriculture bioinformatics and others.

Regional Analysis of Bioinformatics Market:

Globally Americas is the largest market for Bioinformatics. Where in countries like US and Canada play an important role in the growth of the market. Europe is expected to be the second-largest market which is expected to reach US$ XX million by the end of the forecasted period. Furthermore Asia pacific market is expected to be the fastest growing market for Bioinformatics.

Intended Audience

Bioinformatics service providers
Bioinformatics manufacturers
Research and development (R&D) companies
Government research laboratories
Government and independent regulatory authorities

Browse Complete 80 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/bioinformatics-market-2265

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Biochips Market 2018 Market Challenge, Driver, Trends & Forecast to 2023

Market Scenario:

Global Biochips market is expected to grow significantly over the forecast period. The market held a market value of USD 7,300 million in 2017 and is projected to grow at a CAGR of 16.6% over the forecast period. Biochips are intended to function in biological environment, preferably inside living organism.

The factors such as increasing technological advancements in biochips is the major driving factor for the market. Moreover, increasing adoption of personalized medicine, as personalised medicine has many applications in cancer genomics. Furthermore, growing applications of biochips will boost the market growth during forecast period. For instance, biochips can perform thousands of biological reactions operations in few seconds.

However, high cost of the instruments and stringent regulatory guidelines may restrain the growth of the market.

According to national Cancer Institute, in 2018, an estimated 1,735,350 new cases of cancer were diagnosed in the United States and 609,640 people may die from the disease.
Key players:Perkinelmer, Inc., Fluidigm Corporation, Agilent Technologies, Inc., Abbott Laboratories, Bio-Rad Laboratories Inc., Cepheid Inc., Illumina, Inc., GE Healthcare, Thermo Fisher Scientific, Inc, Roche Diagnostics are some of the prominent players in the global biochips market.

Segmentation:The Global Biochips Market has been segmented into type, technology, and end user.

By type, the market has been segmented into DNA chips, lab-on-a-chip, protein chips, cell arrays, and tissue arrays. DNA chips is further segmented into gene expression, SNP genotyping, cancer diagnosis & treatment, genomics, drug discovery, agricultural biotechnology, and others. Lab-on-a-chip is further segmented into clinical diagnostics, genomics, IVD (In-Vitro Diagnostic) & POC (Point of care), Proteomics, Drug Discovery, and others. Protein chips is further segmented into proteomics, expression profiling, diagnostics, high-throughput screening, drug discovery, others.

Based on technology, the market has been segmented into microarrays and microfluidics.

The biochips market, by end user, has been segmented into biotechnology and pharmaceutical companies, hospitals and diagnostics centers, academic & research institutes, and others.

The global biochips market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The biochips market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European biochips market has been segmented into Western Europe and Eastern Europe. The Western Europe biochips market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.

The biochips market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The biochips market in the Middle East & Africa has been segmented into the Middle East and Africa.

Regional Market Summary

Geographically, the Americas is anticipated to dominate the global biochips market owing to the high domestic income, and presence of major market players. Moreover, increasing patient population in US. According to American Cancer Society, the overall estimate of 1,735,350 cases for 2018 equals more than 4,700 new cancer diagnoses each day.

Europe is expected to hold the second largest position in the global biochips market. The market growth in this region is attributed to the presence of strong academic & research base and availability of funding for research in the European countries. For instance, the European Research Council (ERC) provides grants for technological and scientific research conducted within the European Union (EU).

The biochips market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. The Asia-Pacific region is expected to be fastest growing region owing to increasing government focus on biomedical and biotechnology sector and growing number of target population in the region.

The Middle East & Africa has the lowest share of the global biochips market. Majority of the market of the region is anticipated to be held by the Middle East region owing to the growing government initiatives for the healthcare sector.

Browse Complete 90 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/biochips-market-7063

About US:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Tuesday, 5 February 2019

Autoimmune Disease Treatment Market Growth and Restrain Factors Analysis By 2023

Definite causes for the development of autoimmune diseases have not been identified. Thus, the emphasis is on the early diagnosis of the disease. Increasing awareness coupled with large-scale prevalence is likely to aid the proliferation of the autoimmune disease treatment market in the foreseeable future.

Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/5586

Expenditures for the treatment of these diseases are on the rise and is poised to exhibit a similar trend in the forthcoming years. As per the National Institutes of Health (NIH), the U.S., the healthcare expenditure for autoimmune diseases has reached half of that of the cancer expenditure. Furthermore, the introduction of favorable policies for insurance reimbursements are anticipated to augment the market over the next couple of years. However, factors such as side effects, counterfeit drugs, and expensiveness of the treatment are forecasted to check the expansion of the autoimmune disease treatment market across the review period.

Autoimmune Disease Treatment Market – Segmental Analysis:

By disease type, the global autoimmune disease treatment market has been segmented into localized, and systemic. The localized segment is further sub-segmented into multiple sclerosis, inflammatory bowel disease, diabetes, and other. The systemic segment is sub-segmented into rheumatoid arthritis, psoriasis, lupus, and others.

By diagnosis, the autoimmune disease treatment market has been segmented into ELISA, dot blot, line blot, agglutination, double immune diffusion, western blotting, multiplex immunoassay, and others.

By therapeutic products, the global autoimmune disease treatment market has been segmented into drugs and therapeutic and monitoring equipment. The drugs segment is further sub-segmented into biologics, immunosuppressant, anti-inflammatory drugs, corticosteroids, and non-steroidal anti-inflammatory drugs.

By distribution channel, the autoimmune disease treatment market is segmented into hospitals & clinics, diagnostic centers, drug stores, pharmacies, and others.

Regional Outlook:

The regional analysis of the autoimmune disease treatment market spans across Asia Pacific, Americas, Europe, and the Middle East & Africa. Americas signifies a huge potential for growth owing to increasing patient population. In addition, the increase witnessed in the expenditures associated with medical facilities is prognosticated to favor the expansion of the market over the next couple of years. The region has been estimated to gain control over the largest share of the global autoimmune disease treatment market in the forthcoming years.

The government of Europe has extended firm support in favor of research & development in the healthcare sector. This, in turn, is likely to pave the way for the growth of the autoimmune disease treatment market in the region. It is expected to place the region on the second spot globally over 2023.

Asia Pacific has unleashed immense opportunities in the market through rapid developments witnessed in the healthcare sector. The population has also created a positive influence on the growth of the autoimmune disease treatment market by increasing its healthcare expenditures.

Autoimmune Disease Treatment Market – Competitive Dashboard:

Some of the prominent players profiled in this MRFR report are Abbott Laboratories, Genentech Inc., Bayer Schering Pharma AG, Amgen Inc., Biogen Idec Inc., Chugai Pharmaceutical Co. Ltd., Danaher, Bio-Rad, Elan Corporation Plc, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, HYCOR Biomedical, Eli Lilly and Company, Johnson & Johnson Inc., Siemens, Squibb Company, Merck & Co. Inc., and Thermo Fisher Scientific.

Industry News:

In January 2019, Cabaletta Bio, launched out of the University of Pennsylvania, has raised USD 50 Mn for the treatment of for cell-based autoimmune disease.

In January 2019, Banner Life Sciences LLC, a privately held specialty pharmaceutical company, has received tentative approval by the U.S. Food and Drug Administration (FDA) for BAFIERTAM developed for the treatment of relapsing forms of Multiple Sclerosis.

Browse Complete 85 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/autoimmune-disease-treatment-market-5586

About US:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Jaw Surgery Market Analysis 2018 (By Segment, Key Players and Applications) and Forecasts To 2023

Market Synopsis of the Global Jaw Surgery Market

Jaw surgery, also known as orthognathic surgery, is a procedure used to correct a wide range of minor and major skeletal and dental irregularities. It is performed by qualified and skilled oral and maxillofacial surgeons (OMS). Patients with problems related to the jaws, facial asymmetries, and tooth alignment can undergo a jaw surgery. Indications for jaw surgery are maxillary and/or mandibular facial skeletal deformities, speech impairments, chronic jaw or jaw joint pain, facial trauma, and others. It is also used to correct protruding jaw, a congenital defect, or improve the overall facial appearance.

Increasing demand for jaw surgery, extensive use of jaw surgery instruments and devices and technological advancement in healthcare are the major drivers for the growth of the market. Furthermore, increasing healthcare expenditure and overall growth of healthcare industry has also influenced the market growth. Splendid research in the field of cosmetology also boost the market. However, the growth of the market is restrained by unawareness about the advantages of the procedure. Fierce competition among key players in the market restricts the entry of key players.

Additionally, increasing number of maxillary and mandibular surgeries also fuels the growth of the market across the globe.

The global jaw surgery market is expected to grow at a CAGR of 3.7% during the forecast period.

Key Players in the Global Jaw Surgery Market

Some of the key players in this market are Integra LifeSciences Corporation (U.S.), The Amato Centers for Facial Surgery (U.S.), The Restful Jaw Company, LLC. (U.S.), Millennium Surgical Corp (U.S.), Scanlan International. (U.S.), Novo Surgical Inc. (U.S.), HAAG-STREIT GROUP (U.S.), Eurosurgical (U.K), Sklar Surgical Instruments (U.S.), and others.

Segments

The global jaw surgery market is segmented on the basis of instruments, indication, and end user.

On the basis of instruments, market is segmented into curettes, elevators, forceps and needle holders, retractors and speculums, and others.

On the basis of indication, the market is segmented into maxillary and/or mandibular facial skeletal deformities, speech impairments, chronic jaw or jaw joint pain, facial trauma, and others.

On the basis of end user, the market is segmented into hospitals, clinics, and others.

Regional Analysis of the Global Jaw Surgery Market

America holds the first position in the market for jaw surgery owing to rising demand for jaw surgery and increasing number of clinics, and hospitals providing treatment for jaw surgery. In Americas, North America is the largest market owing to the presence of key player in the market that provide product and instruments for jaw surgery.

Europe is the second largest market for jaw surgery. In Europe, increasing expenditure on healthcare, growing economic support, and rising funding for research and development in healthcare also fuels the growth of the market. Germany and France are the biggest contributors to the growth of the market in Europe owing to the rising awareness about jaw surgery, and its advantages for improving facial appearance among the people. Additionally, overall growth of medical device industry further fuels the market growth.

The market in Asia Pacific is expected to grow at the fastest pace and is driven by the rising per capita income, increasing adoption of western culture has led the consumer inclination toward aesthetics, and growing demand for surgical procedures as a treatment option, due to a considerable prevalence of facial defects. China, and Japan are the major contributors of the growth of the market. This growth is attributed to an increasing demand of technologically advanced medical devices such as 3D imaging, and other orthodontic technologies, and availability of highly qualified medical personnel such as orthodontists and surgeons.

The Middle East & Africa also show a steady rise in the market owing to low technology penetration and increasing awareness about availability of surgical procedures in orthognathics and orthodontics. In the Middle East & Africa, Middle East captures the largest market share for jaw surgery owing to the availability of better healthcare infrastructure and a wide scope for research.

Browse Complete 110 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/jaw-surgery-market-5077

About US:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Urine Cytology Market - Market Demand, Growth, Opportunities and Analysis of Top Key Player Forecast To 2023

Market Synopsis of the Global Urine Cytology Market

Cytology is an emerging field in healthcare that plays an important role in the diagnosis of various diseases such as cancer, and chronic diseases. It involves the examination of cells of the body under a microscope. In urine cytology, urine specimen is collected from the patient to determine the functioning of the cells. The healthcare provider may recommend urine cytology examination if the patient has symptoms such as unexplained blood in the urine, burning and pain during urination. It is commonly used for the diagnosis of infection, inflammatory disease of the urinary tract, cancer of kidney, bladder, ureter, urethra, and others.

Rising prevalence of chronic diseases such as urinary tract infection, and cancer, increasing demand for urine tests, and the presence of key players in the market are important drivers that accelerate the growth of the market. Increasing demand for testing kits for home care is another key driver for the market growth. Additionally, increasing focus on diagnostic services in both the developing and developed regions across the globe also influences the growth of the market. Furthermore, replacement of manual instruments by automated ones in the hospitals and diagnostic centers also fuels the progress of the market. Although competition among key players in the market may act as a barrier for new entrants.

The global urine cytology market is expected to grow at a CAGR of 5.2% during the forecast period

Segments

The global urine cytology market is segmented on the basis of product, indication, and end user.

On the basis of product, market is segmented into urine cytology instrument, urine cytology kit, and others. Product is further segmented into automated, and manual instrument.

On the basis of indication, the market is segmented into urinary infection, inflammatory disease, cancer, and others. Cancer is further segmented into kidney, bladder, ureter, and urethra.

On the basis of end user, the market is segmented into hospitals & clinics, diagnostic centers, home care, and others.

Regional Analysis of the Global Urine Cytology Market

America acquires a leading position in the market for urine cytology, owing to the rising prevalence of various urinary tract infection, inflammatory disease, and cancer. Additionally, presence of key players manufacturing urine urology kits, and devices. The major players are engaged in various strategic approaches such as merger, acquisition, partnership, collaborations, and new product, and others to strengthen their position in the market. ThermoFischer Scientific, BD, and Sigma- Aldrich are 3 major players in the U.S. market.

Europe is the second largest market for urine cytology owing to the availability of funds for research and development activities. Also, rising prevalence of cancer, increasing demand for diagnostic services and rising awareness about urine cytology for the diagnosis of diseases for urinary tract the market growth.

The market in Asia Pacific is expected to grow at the fastest pace and is driven by the rising prevalence of urinary tract infection which would act as a major risk factor for the growth of the market. Furthermore, rising awareness about the use of urine cytology for the diagnosis of urinary tract infection also influences the growth of the market. Additionally, changing lifestyle and rising geriatric population also drive the growth of the market. Furthermore, rising expenditure on healthcare by the developing countries in Asia Pacific also fuels the growth of the market.

The Middle East & Africa also show a steady rise in the market owing to high prevalence of chronic diseases such as infection, and cancer and improving healthcare infrastructure. The United Arab Emirates, and Saudi Arabia are the largest contributors to the growth of the market owing to the availability of specialty healthcare resources and demand for diagnostics devices, and test kits. Increasing demand for new treatment options for chronic diseases also influences the market growth in the Middle East & African countries. In Africa, the market shows positive growth owing to increasing prevalence of infectious diseases and demand for healthcare services in the developing and under developing countries.

Key Players in the Global Urine Cytology Market

Some of the key players in this market are ThermoFischer Scientific (U.S.), BD (U.S.), Sigma- Aldrich (U.S.), Severn Biotech Limited (U.K), Bio-Techne (U.S), Laboratory Corporation of America Holdings (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), and others.

Browse Complete 110 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/urine-cytology-market-5116

About US:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Injectable Drug Delivery Devices Market Growth and Restrain Factors Analysis By 2023

Market scenario:

Injectable drug delivery devices include an array of medical devices ranging from conventional syringes, needle-free injectors to auto and pen injectors. The demand for such devices has witnessed a rise in recent years on account of the mounting prevalence of chronic diseases across the globe. Market Research Future (MRFR) predicts the growth of the global injectable drug delivery devices market to be splendid at a CAGR of 11.5% over the forecast period of 2018-2023. The global injectable drug delivery devices market is likely to surpass a valuation of USD 31,900 Mn by the end of 2023.

The growth of the global injectable drug delivery devices market is sustained by the high prevalence of chronic diseases such as diabetes and cancer. Injectable drug delivery devices are used in the treatment of such medical conditions which spurs the demand for injectable drug delivery devices. In addition, owing to their use of use, injectable drug delivery devices are being progressively adopted. Other contributing factors to the growth of the market include key developments within the market as a result of R&D and clinical trials. Additionally, the rise in a number of FDA approvals also boosts the growth of the market. Introduction of advanced injectable drug delivery devices with superior functional capabilities is anticipated to reflect positively on the market growth.

Conversely, the growth of the global injectable drug delivery devices market might be restricted by the underlying risk of cross-contamination. Nevertheless, the proliferation of vaccination programs across underdeveloped countries provides lucrative growth opportunities for market expansion.

Segmentation

The global injectable drug delivery devices market has been segmented based on device, therapeutic application, usage pattern, site of delivery, distribution channel, and facility of use.

By device, the global injectable drug delivery device market has been segmented into conventional injection devices and self-injection devices. The conventional injection devices segment has been further segmented into material, product, and utility. The self-injectable devices segment has been further segmented into needle-free injectors and pen systems and auto-injectors. The conventional injection devices segment commands the largest share of the global market.

By therapeutic application, the global injectable drug delivery device market has been segmented into autoimmune diseases, hormonal disorders, cancer, and others. The autoimmune diseases segment is the largest segment by therapeutic application.

By usage pattern, the global injectable drug delivery devices market has been segmented into curative and immunization. The curative segment is expected to be the fastest growing segment over the forecast period.

By site of delivery, the global injectable drug delivery devices market has been segmented into intramuscular, subcutaneous, and intradermal. The intramuscular segment is the largest segment.

By distribution channel, the global injectable drug delivery devices market has been segmented into hospital & retail pharmacies and online platforms. The hospitals & retail pharmacies segment is the largest segment while the online platform segment is expected to be the fastest growing segment by the end of 2023.

By facility of use, the global injectable drug delivery devices market has been segmented into hospitals and clinics, home care settings, and others.

Regional Analysis

By region, the global injectable drug delivery devices market has been segmented into the Americas, Asia Pacific (APAC), Europe, and the Middle East and Africa (MEA).

The Americas is leading the global injectable drug delivery devices market. Expansion of the biotechnology industry, the surging prevalence of chronic diseases and a robust healthcare sector spur the growth of the market. Also, the region is a frontrunner in the incorporation of technologically advanced healthcare solutions which further accelerates the growth of the market.

Europe held the second largest share of the global market in 2017 and is likely to reach USD 13,074.3 Mn by the end of 2023. High adoption of advanced healthcare services coupled with extensive R&D efforts can be credited for the growth of the Europe market.

APAC market for injectable drug delivery devices market is expected to register the highest CAGR of 11.45 OVER TEH FORECAST period. High demand for advanced healthcare in rapidly growing economies drives the APAC market.

Lack of awareness and less exposure to primary healthcare services in the underdeveloped regions of the Middle East & Africa is expected to impede the growth of the market.

Competitive Landscape

The key players in the global injectable drug delivery devices market include Eli Lilly and Company, Antares Pharma, Inovio Pharmaceuticals Inc., Eisai Co. Ltd., Becton, Sanofi, Johnson & Johnson Services Inc., Novo Nordisk, AstraZeneca, F.Hoffmann-La Roche AG, Teva Pharmaceutical Industries Ltd., Pfizer Inc., Dickinson and Company, Novartis AG, and Mylan N.V.

Browse Complete 80 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/injectable-drug-delivery-devices-market-1211

About US:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Verrucous Carcinoma Market - Granular Market Report and Review, 2018

Market Scenario:

Verrucous carcinoma (VC) is a rare type of squamous cell carcinoma and is categorized under head and neck cancer. It is mainly caused due to the chewing of tobacco or snuffing it orally. It is also called as snuff dipper's cancer. Verrucous carcinoma most commonly occurs at oral sites but is also observed in head and neck genital locations. It is mainly observed in males than in females and is found in the age group of 50 to 80 years. The key factor responsible for influencing this market is the increasing prevalence of oral cancer. It may also be caused due to lifestyle factors such as smoking tobacco or marijuana, alcohol consumption, and others. Other key factors such as a change to sedentary lifestyle, growing consumption of alcohol, increasing tobacco users of dip, snuff, increase in smoking, rising family history of cancer prevalence, and increasing prevalence of sexually transmitted diseases by human papillomavirus are contributing towards the growth of the market. According to the World Health Organization in 2015, globally 1.1 billion people smoked tobacco. This is expected to provide favorable backgrounds for market growth during the forecast period.

However, factors such as the high cost of surgical procedures, expensive chemotherapy treatments, and side effects associated with treatments are expected to restrict the market growth during the forecast period.

Key players

Some of the key players in the global verrucous carcinoma market are Bristol-Myers Squibb Company (US) Qilu Pharmaceutical Co., Ltd. (Asia Pacific), Teva Pharmaceutical Industries Ltd. (Israel), Eli Lilly and Company. (US), F. Hoffmann-La Roche Ltd (Europe), Merck & Co., Inc. (US), Novartis AG (Europe), Pfizer Inc. (US), and others.

Segmentation

The global verrucous carcinoma market is segmented on the basis of diagnosis, treatment, and end-user. The verrucous carcinoma market, by diagnosis, is categorized into biopsy, endoscopy, and imaging tests. Imaging tests are categorized into computerized tomography scans, magnetic resonance imaging, and positron emission tomography scans. On the basis of treatment, the market is segmented into surgery, radiation therapy, chemotherapy, and targeted drug therapy. The surgery category consists of surgical excision and mohs micrographic surgery. Chemotherapy consists of bleomycin, 5-fluorouracil, cisplatin, methotrexate, and others. On the basis of end-user, the market is segmented into hospitals and clinics, ambulatory surgical centers, diagnostic centers, research centers, and others.

On the basis of region, the global verrucous carcinoma market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas is sub-segmented into North America and South America. The North American region is further segmented into the US and Canada. The European region is divided into two, namely, Western Europe and Eastern Europe. Western Europe is further classified into Germany, Italy, France, the UK, Spain, and the rest of Western Europe. The Asia-Pacific region is sub-segmented into Japan, China, India, Australia, the Republic of Korea, and the rest of Asia-Pacific. The Middle Eastern and African region is sub-segmented into the United Arab Emirates, Saudi Arabia, Oman, Kuwait, Qatar, and the rest of the Middle East and Africa.

Regional Market Summary

It is estimated that North America dominated the global verrucous carcinoma market owing to the increasing innovations in clinical practice, cancer research, and access to cancer treatment in this region. The American Cancer Society in August 2018 granted USD 15,866,878 for head and neck cancer research projects. This influences the market growth in this region

According to the World Health Organization’s Fact Sheet on Tobacco and Oral Health (2018), Europe has the highest prevalence of tobacco smoking among adults that is 28% of adults in Europe are engaged in tobacco smoking. Such a high prevalence of smoking in this region facilitates the market growth. Europe stood second largest in the verrucous carcinoma market owing to the increasing use of tobacco.

Asia-Pacific was projected to be the fastest growing region for the global verrucous carcinoma market in 2017. The market is expected to witness growth owing to the rising prevalence of oral cancer, changing lifestyle, and increasing tobacco use within the population. The Center for Cancer Control and Information Services estimated 15,600 cases of oral cavity and pharynx cancer in 2017 in Japan. Such a high incidence of oral cancer favors the market growth in this region.

The Middle East and Africa holds the least share in the global verrucous carcinoma market due to the presence of poor health expenditure and economically diverse countries. However, the market is expected to witness growth due to increasing cancer care programs in the Middle East.

Browse Complete 90 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/verrucous-carcinoma-market-6367

About US:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com